Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Targeting CK2 for cancer therapy using a nanomedicine approach
Khalil Ahmed
, Gretchen Unger
, Betsy T. Kren
,
Janeen H. Trembley
Laboratory Medicine and Pathology
Cellular Mechanisms of Cancer
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
9
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting CK2 for cancer therapy using a nanomedicine approach'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Therapy
100%
Nanomedicine
100%
Tenfibgen
100%
Cargo
50%
RNA Interference
33%
Malignant Cells
33%
Xenograft Tumor
33%
Protein Expression
16%
Malignancy
16%
Cell Proliferation
16%
Small Interfering RNA (siRNA)
16%
Small Molecules
16%
Cancer Cells
16%
Apoptosis
16%
Nanocapsules
16%
Therapeutic Efficacy
16%
Metastatic Cancer
16%
Oligonucleotides
16%
Overall Survival
16%
Therapy Approaches
16%
Single-stranded DNA (ssDNA)
16%
Systemic Administration
16%
Inflammation Response
16%
Biodistribution
16%
Tumor Reduction
16%
No Toxicity
16%
Tumor Proliferation
16%
Chimeric Oligonucleotides
16%
Cancer Site
16%
Nanoencapsulation Technology
16%
CK2 Inhibitors
16%
Cell Delivery
16%
Early Inflammation
16%
Encapsulation Technology
16%
Promising Target
16%
Serine/threonine Kinase
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Nanomedicine
100%
4,5,6,7 Tetrabromo 2 Dimethylamino 1h Benzimidazole
50%
Oligonucleotide
50%
Nanocapsule
25%
Small Interfering RNA
25%
Tumor Growth
25%
Overall Survival
25%
Biodistribution
25%
Systemic Administration
25%
Single Stranded DNA
25%
Inflammation
25%
Neoplasm
25%
Casein Kinase
25%